What Are Analyst Opinions Regarding Adverum Biotechnologies Inc. (ADVM)?

How have the shares performed?


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Adverum Biotechnologies Inc. (ADVM) saw downtrend of -4.62% in the recent trading with $3.72 being its most recent. The current price level -86.21% lower than the highest price of $26.98 marked by the stock while trading over the past 52-weeks, whereas it is -1.59% higher than the lowest price of $3.78 the company dropped to over past 52-weeks. The latest news story on ADVM appeared in Benzinga under the title “Adverum’s Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced Patients” on May-03-21.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Squeezing the time span to 30 day period shows us the stock is currently trading -65.71% below one month high and is +1.09% above of the lowest during that time. Looking into the simple moving average, Adverum Biotechnologies Inc. (ADVM)’s stock stands at a SMA-50 of $10.04 while that of 5-day is reading $6.29.

Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ADVM’s SMA-200 as of now is $12.28.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.50 for the stock.

Adverum Biotechnologies Inc. Earnings – What Happened With ADVM

Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Adverum Biotechnologies Inc. (ADVM) last released financial results for the quarter that ended 12/30/2020, posting a surprise factor of -21.90% for net revenue.

ADVM – Adverum Biotechnologies Inc. Stock Earnings Estimates

The perspective of Adverum Biotechnologies Inc. (NASDAQ:ADVM)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.32 for stock’s EPS in the current quarter. 9 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.39.

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 97.60 million. ADVM does have institutional investors; and they hold 98.70% of the stock.

Adverum Biotechnologies Inc. – Insider Activity and Holdings

Moreover, the latest SEC filings also revealed that stock came across 3 new insider purchases involving 40,000 shares. On the other hand, ADVM declared 12,533 shares have been sold in 2 insider transactions over the past three months.

As on Dec 30, 2020, RA Capital Management, L.P. was the top most holder in Adverum Biotechnologies Inc. (NASDAQ:ADVM) with an ownership of 9.5 million shares of the company or 9.70% of the stake worth $103.01 million. The filing also reveals Avoro Capital Advisors LLC as the second largest holder in the company with a control over 8.17% of the outstanding shares. Its stake is worth $86.72 million for having 8.0 million shares in hand.

RTW Investments LP also came holding a key position in the company during the recent quarter and it now holds 7.38% of the outstanding shares. With this there are now 220 institutions which have possession in ADVM’s shares.

Currently, the stock has been recommended as Moderate Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.50 for the stock.

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Adverum Biotechnologies Inc. was 20.82 while posting a debt to equity ratio of 0.00. The count was 6.05 for long-term debt to equity ratio.

Adverum Biotechnologies Inc.’s return on equity, or ROE, is -31.60%, compared to the industry average of -44.41% for Healthcare – Biotechnology. Although this indicates that ADVM uses its equity well, the metric will vary significantly depending on the industry.

Leave a Comment

Your email address will not be published. Required fields are marked *

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.